https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Lung cancer treatment patterns and factors relating to systemic therapy use in Australia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46698 Wed 13 Mar 2024 08:07:19 AEDT ]]> Cancer incidence and cancer death in relation to tobacco smoking in a population-based Australian cohort study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48997 35 cigarettes/day. Lung cancer risk was lower with quitting at any age but remained higher than never-smokers for quitters aged >25y. By age 80y, an estimated 48.3% of current-smokers (41.1% never-smokers) will develop cancer, and 14% will develop lung cancer, including 7.7% currently smoking 1-5 cigarettes/day and 26.4% for >35 cigarettes/day (1.0% never-smokers). Cancer risk for Australian smokers is significant, even for 'light' smokers. These contemporary estimates underpin the need for continued investment in strategies to prevent smoking uptake and facilitate cessation, which remain key to reducing cancer morbidity and mortality worldwide.]]> Wed 03 May 2023 12:03:16 AEST ]]> Health services costs for lung cancer care in Australia: estimates from the 45 and up study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40089 p<0.0001), smoking (p<0.0001) and unknown stage (p = 0.002). There was no evidence of differences by year of diagnosis or sex (both p>0.50). For 465 cases diagnosed 2014–2015, 29% had subsidised molecular testing for targeted therapy/immunotherapy and 4% had subsidised targeted therapies. Conclusions: Lung cancer healthcare costs are strongly associated with survival-related factors. Costs appeared stable over the period 2006–2013. This study provides a framework for evaluating the health/economic impact of introducing lung cancer screening and other interventions in Australia.]]> Fri 15 Jul 2022 10:04:25 AEST ]]>